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beneﬁ ciaries who were enrolled in an MA-PD or a drug plan with drug deductibles, 
tiered copayments, or mailorder services in the plan beneﬁ t design were more likely 
to experience CRN.
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OBJECTIVES: The health care utilization and costs among commercially insured 
women with a diagnosis of Female Sexual Dysfunction (FSD) and Hypoactive Sexual 
Desire Disorder (HSDD) in the United States. METHODS: The Thomson Reuters
Marketscan Database was used to identify women aged 18–64 with an ICD-9-CM 
coded diagnosis of FSD, including a subset with HSDD from January 1, 1998-Sep-
tember 30, 2006. A control group of women with no diagnosis of any sexual dysfunc-
tion was matched 3:1 to cases based on age, health plan and enrollment period.
Controls were assigned the index date of their matched case. Health care utilization 
and costs were examined in the year prior (“pre-period”) to and following index 
(“post-period”). RESULTS: A total of 4831 women were coded as FSD (59% as
HSDD) and matched to 14,493 controls. The FSD group had more outpatient visits
and services in both the pre- (22.2 vs. 16.2, p  0.001) and post- (25.4 vs. 17.7, p 
0.001) periods compared with their matched controls. They also consistently ﬁ lled 
more prescriptions in the pre- (14.5 vs. 11.5, p  0.001) and post- (16.2 vs. 7.2, p 
0.001) periods. Nearly identical patterns were observed in the HSDD group. These 
higher levels of utilization resulted in costs that were higher for FSD and HSDD 
women relative to their matched controls in the pre-period ($1296 and $ 1146 respec-
tively). Similar patterns of increased health care utilization were also seen in the post-
period for both FSD and HSDD patients ($1,190 and $897 respectively). The most
signiﬁ cant drivers of health care costs for both groups were outpatient medical services
(including professional visits, outpatient surgeries, and laboratory expenditures) and
total prescription medication costs. CONCLUSIONS: Women diagnosed with FSD
and HSDD use signiﬁ cantly more health care services than women without diagnosed 
sexual dysfunction. The resulting higher costs are driven by a greater use of outpatient 
services and prescription medications.
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OBJECTIVES: To understand current management (utilization, compliance) with
palivizumab prophylaxis of children at high-risk of RSV infection in Canada. 
METHODS: A prospective, observational, registry of infants at high risk for RSV who
received at least one dose of palivizumab during the 2006 to 2008 RSV seasons from 
24 sites. Neonatal and demographic data were collected upon enrollment. Data on
palivizumab utilization and compliance, including outcomes related to a respiratory 
infection were collected monthly until the full course of palivizumab was completed
or at the end of the relevant RSV season. RESULTS: A total of 2910 infants were
enrolled, age two days to 47 months (mean  5.5 months). In total, 54.4% were male, 
62.2% Caucasian, average gestational age (GA) was 32.0 o 6.8 completed weeks.
2079 (71.4%) infants received palivizumab because they were premature only (i.e.
a35 completed weeks GA), 255 (8.8%) required oxygen, 288 (9.9%) had congenital 
heart disease and 288 (9.9%) were prophylaxed for other risk factors such as CNS
disorders, airway anomalies and cystic ﬁ brosis. Compliance was high; 77.8% received 
at least four injections of palivizumab between September and June each season.
Overall 12, 973 doses were given. No directly related serious adverse events were
identiﬁ ed. A total of 159 infants had 194 hospitalizations for respiratory tract infec-
tions (hospitalization rate 5.5%) and rates were highest in those with chronic lung 
disease (9.8%, p  0.006). The RSV positive hospitalization rate was only 0.96%. 
CONCLUSIONS: The RSV hospitalization rate observed in the 2006–2008 RSV
seasons was lower than that found in several published reports (range1.3%–5.3%). 
The rates of RSV hospitalization may be decreasing for various reasons such as high
compliance with palivizumab prophylaxis, variability in RSV epidemiology, hospital
admission criteria and preventive education.
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OBJECTIVES: Alprazolam is a frequently prescribed benzodiazepine associated with 
abuse and misuse that can lead to fatalities. This study’s aims were to: 1) describe the 
characteristics of alprazolam-related death cases; 2) describe the comorbidities, co-
ingested drugs, and mean alprazolam concentrations of decedents; and 3) compare
characteristics between alprazolam and non alprazolam-related death cases.
METHODS: Data from all drug-related deaths in West Virginia from January 1,
2005 to November 16, 2007 were extracted from the Forensic Drug Database. Chi 
square tests compared categorical descriptive statistics between alprazolam and non-
alprazolam cases. One-way ANOVA compared mean alprazolam blood concentra-
tions based upon numbers of other ingested drugs. RESULTS: Of the 1199 drug-related 
deaths in the database, alprazolam was a contributing cause in 204 (17.0%) cases. It 
was involved in an increasing number of drug-related deaths over time. The mean age 
of alprazolam cases was 39.6 (11.2) years; most were male (66.3%) and white 
(96.0%), with the deaths ruled accidental (90.2%). There was a prescription for
alprazolam in over half the cases (52.5%); approximately one-third (33.8%) had a
history of substance abuse or cardiovascular disease. At least one other drug was a 
contributor to death in 97.5% of the alprazolam cases, with an opiate detected in 
most cases (88.7%). The mean alprazolam blood concentration was signiﬁ cantly 
higher when taken alone than when ingested with one or more drugs (p  0.001). 
More alprazolam decedents were obese (43.9%) compared to non-alprazolam dece-
dents (32.9%) (p  0.005). Alprazolam cases had a signiﬁ cantly greater average
number of drugs implicated in death (2.9  1.0) than non-alprazolam cases (2.3  1.3) 
(p  0.001). CONCLUSIONS: Alprazolam-associated deaths are a signiﬁ cant public 
health problem in West Virginia; these cases have characteristics that can differ from
other drug death cases. Certain drug combinations involving alprazolam may pose a 
greater risk for serious adverse events.
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OBJECTIVES: Many patients with major depressive disorder (MDD) suffer from
chronic pain (CP) and sleep disturbances (SD). Little is known about associations
between the use of hypnotics/anxiolytics for these conditions and the use of antidepres-
sants in real-world clinical settings. This study examined the use of hypnotics and 
anxiolytics, their associations with CP and SD, and initiation of serotonin-norepineph-
rine reuptake inhibitors (duloxetine and venlafaxine XR) in a large managed-care 
population of patients with MDD. METHODS: A total of 153,913 patients who had
at least 1 diagnosis of MDD during the year 2006 were selected from a large com-
mercially insured administrative claims database. The analytic sample consisted of 
47,109 (30.6%) males and 106,804 (69.4%) females, with a mean age of 43.6 years
(SD  12.7). In accordance with ICD-9-CM, CP was deﬁ ned as any pain of the fol-
lowing 6 categories: headache, rheumatoid arthritis, osteoarthritis, low back pain, 
ﬁ bromyalgia, and neuropathic pain. Hypnotics/anxiolytics were classiﬁ ed into 3 cate-
gories: benzodiazepines (BENZ), non-benzodiazepine hypnotics (NBENZH), and non-
benzodiazepine anxiolytics (NBENZA). RESULTS: Of the 153,913 patients with 
MDD, 35.5% had CP; 5.3%, SD; and 7.3%, CP plus SD. Over the 1-year study
period, 33.1% of patients were prescribed BENZ; 16.9%, NBENZH; and 6.1%,
NBENZA. Of patients with MDD, patients also diagnosed with CP and SD were most 
frequently prescribed NBENZH, BENZ, and NBENZA (36.4%, 47.7%, 9.6%), fol-
lowed by patients with SD (30.2%, 36.7%, 6.4%), CP (18.7%, 39.9%, 7.4%), and 
MDD only (11.6%, 26.1%, 4.6%). Prior use of BENZ (OR  1.5, 95% CI  1.4–1.6), 
NBENZH (OR  1.6, 95% CI  1.5–1.7), and NBENZA (OR  1.2, 95% CI  1.1–
1.3) was signiﬁ cantly associated with initiation of duloxetine compared with venla-
faxine XR. CONCLUSIONS: Hypnotics and anxiolytics are commonly used in MDD
patients. CP and SD are associated with increased use of hypnotics and anxioloytics 
in MDD patients. Prior use of hypnotics and anxioloytics may be associated with
antidepressant selection.
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OBJECTIVES: To assess ethnic differences in the prevalence, physician diagnosis and 
symptomology of depression. METHODS: Data were taken from the 2008 US
National Health and Wellness Survey (NHWS), a self-reported, Internet-based study
of the disease status, attitudes, habits, and outcomes of adults age 18. Ethnic groups 
included whites, blacks, Hispanics and Asians. Respondents self reported experiencing 
depression, depression diagnosed by a physician, and experiencing the following in 
the previous month: bothered by feeling down, depressed, or hopeless; bothered by 
having little interest or pleasure in doing things. Prevalence was calculated using fre-
quency weights based on age, gender and race. Chi-square analyses were conducted 
to assess statistically signiﬁ cant differences. RESULTS: Of the 61,016 respondents,
22.2% (Projected 53.8M; 25%) reported experiencing depression within the previous 
year. There were signiﬁ cant (p  0.05) variations across ethnic groups: White  39.5M, 
25.8%; Black  4.9M, 19.8%; Hispanic  8.1M, 27.6%; Asian  1.3M, 16.1%). 
Among those who report experiencing depression, whites were most likely to be
diagnosed (77.0%) compared with 60.8% of blacks, 62.8% of Hispanics, and only
48.4% of Asians, who were least likely to be diagnosed. Among those who did not
self-report experiencing depression, 11.2% of whites, 12.8% of blacks, 13.1% of 
Hispanics, and 13.46% of Asians experienced one depression symptom and 9.6% of 
whites, 11.9% of blacks, 13.2% of Hispanics, and 12.2% of Asians experienced both
depression symptoms (p  0.05). CONCLUSIONS: While there is signiﬁ cant ethnic 
variation in prevalence of self-reported depression, there is even greater ethnic varia-
tion in diagnosis among patients experiencing depression. Also, recognition of symp-
